poorly defined tumor of 3 cm that diffusely infiltrated the myometrium, enlarged pelvic nodes and bone lesions in the sacrum and acetabulum; suggestive of a malignant uterine neoplasm with lymphatic and bone metastases. Based on these findings, the patient received 6 cycles of chemotherapy with cisplatin and etoposide. Another PET/TAC scan was performed, four months after the beginning of chemotherapy, to evaluate the response to treatment. Pulmonary lesions were not detectable, and a demining of the pelvic pathological lesions (uterus [SUV of 2.42], lymphoid and bone [SUV of 3.8]) was observed ( Figure 4 ). Tumor markers values after finishing chemotherapy were normal: Ca 125 36 U/mL, SCC 2.2 ng/mL, neuron specific enolase 12 ng/mL, except CEA 5.9 ng/ml and Chromogranin A 1180 ng/mL.
Our multidisciplinary oncology committee decided to perform a debulking surgery, including a hysterectomy and the removal of the vaginal tumor and enlarged pelvic lymph nodes, six months after diagnosis. The histologic analysis of the uterus and lymph nodes revealed a high grade LCNEC, affecting endometrium, lymph nodes and vagina. The tumor was positive to chromogranin and synaptophysin in 80% and 50% of neoplastic cells respectively. Lanreotide (a synthetic somatostatin analog) autogel 120 mg/28 days, as maintenance treatment, was prescribed due to an octreoscan captation before surgery.
One month later, the patient was admitted in the hospital due to hemoptisis. A pulmonary angio-CT was performed revealing multiple cavitated pulmonary nodules. Second line chemotherapy with Topotecan was indicated. 18 months after It is difficult to give a preoperatory definitive histologic diagnosis on small specimens [1, 5] . In our case, this was possible as we were able to obtain more material from two biopsies of the endometrium and vagina.
The age of diagnosis of the 16 cases described in literature, range from 40 to 88 years old with a mean of 63.4 years old [1] , the majority of which were postmenopausal, like our case (58-years old). The most common initial symptom was postmenopausal bleeding (12/17 cases), like our patient's case. Smoking and endometrial LCNEC has yet to be investigated thoroughly. Only one study reported a patient with LCNEC who had smoked two packs of cigarettes per day for more than 30 years [9] . Our patient smoked only two packets of cigarettes per year, which would not appear to be consequential.
Makihara et al observed MR findings of LCNEC which seemed to mimic MRI findings in other poorly differentiated endometrial adenocarcinomas and uterine sarcomas [10] .
Blood tumor marker Ca-125 could be elevated in cases of LCNEC [1] ; in our case Ca-125 was elevated to 200. Tumor markers levels could be used for monitoring treatment response. Treglia et al observed that 18F-FDG PET/TAC may provide useful prognostic information in patients with high-grade neuroendocrine tumors, like our patient's case [11] .
It is clear that multi-modality approach is required for the treatment of this rare tumors with a poor prognosis.
There is no surgical standard for this rare histology and treatment depends on stage of the tumor. As in our case, hysterectomy and bilateral salpingo-oophorectomy is the surgical procedure more commonly used (11/16) [1] . There are only 4 recorded cases of radical hysterectomy being performed. Lymph node dissection is performed in 9 of the 16 cases described in literature [1] ; in our case we performed a pelvic debulking of enlarged suspicious pelvic lymph nodes.
Omentectomy was performed in 8 cases of the 16 described in literature [1] . Although complete surgical staging with omentectomy and pelvic and paraaortic lymphadenectomy is required for accurate staging of uterine cancer, Nguyen et al observed 8 of the 13 reported cases of endometrial LCNEC presented in advanced FIGO stage III or IV disease. Given the poor prognosis of the disease, even following surgical debulking, some authors may consider administering neoadjuvant chemotherapy when a preoperative diagnosis is possible [12] , as we conducted on our patient.
There is limited data concerning adjuvant or neoadjuvant treatment of LCNEC of the endometrium, also in first line setting.
Platinum and Etoposide based chemotherapy is generally used, by extrapolating data from LCNEC of the lung, since data for cervical and uterine endocrine tumors is limited [13, 14] . We used Etoposide and Platinum as first line therapy, with partial response of the disease. After relapse, we treated the patient with second line chemotherapy with Topotecan, based on LCNEC recommendations. Other therapies, in second line chemotherapy, reported by other authors are;
cyclophosphamide/doxorubicin/Vincristine (CAV) and irinotecan/platinum (IP) [10,14-16).
As was our case, two authors have reported the use of somatostatin analog with combination with chemotherapy for the treatment of two advanced cases of endometrial neuroendocrine tumors. One case demonstrated a partial response, while a second patient exhibited a progression of the disease [6, 17] . Astatine-211-labeled octreotide (somatostatin analog) has been described as a potential radiotherapeutic agent for neuroendocrine lung tumors with promising results [18] .
Radiotherapy is also used by other authors as adjuvant treatment for LCNEC, 7 of the 16 patients treated with radiotherapy,
